Roche 'extremely open' to talks with Novartis: report

October 1, 2013

The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.

"If the right opportunity comes up, we would be extremely open to talk with Novartis, as we would be with other players," Severin Schwan told the British financial daily.

"If it makes sense for both companies, why not sit together and talk? It's a very professional relationship we have with Novartis," he added.

Alliances in the pharmaceutical industry are becoming increasingly important as the cost of developing new drugs continues to rise.

Novartis holds a 33-percent stake in Roche, but the company remains under family control.

Schwan's comments come as leadership in the two giants has undergone dramatic shifts.

Last month, Roche announced that Lufthansa chief Christoph Franz would be proposed to take over as board chairman, while Joerg Reinhardt took the reins of Novartis in August from Daniel Vasella, who spent 17 years in the driving seat.

The outgoing Vasella did not hide his belief that a merger of the two companies could make sense.

It never happened though, and Roche has remained firmly in the hands of family shareholders, who own 50 percent of the , and many market observers have speculated Novartis might give up the strategic stake.

Schwan however said Tuesday the two companies had not discussed the future of the Novartis holdings in Roche.

Explore further: Roche extends its hostile takeover bid for Illumina

Related Stories

Novartis Q4 net profit rebounds to $2.1 billion

January 23, 2013

(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013

Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Lufthansa boss quits for Roche pharmaceuticals (Update)

September 16, 2013

The head of German airline Lufthansa, Christoph Franz, will step down at the end of his current contract in May 2014 to head the board of directors at Roche pharmaceutical group, the companies announced on Monday.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.